A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib
Xiao Chu,Yuan Li,Zhengfei Zhu
DOI: https://doi.org/10.1016/j.jtho.2018.05.022
IF: 20.121
2018-01-01
Journal of Thoracic Oncology
Abstract:Transformation of SCLC from lung adenocarcinoma (LADC) was regarded as a rare mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKIs),1Oser M.G. Niederst M.J. Sequist L.V. Engelman J.A. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.Lancet Oncol. 2015; 16: e165-e172Abstract Full Text Full Text PDF PubMed Scopus (562) Google Scholar, 2Zhao J. Shao J. Zhao R. et al.Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma.Thorac Cancer. 2018; 9: 129-135Crossref PubMed Scopus (7) Google Scholar, 3Engelman J.A. Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Clin Cancer Res. 2008; 14: 2895-2899Crossref PubMed Scopus (595) Google Scholar, 4Lee J.K. Lee J. Kim S. et al.Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas.J Clin Oncol. 2017; 35: 3065-3074Crossref PubMed Scopus (268) Google Scholar which occurs months (range 10–58 months) after effective TKI treatment.1Oser M.G. Niederst M.J. Sequist L.V. Engelman J.A. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.Lancet Oncol. 2015; 16: e165-e172Abstract Full Text Full Text PDF PubMed Scopus (562) Google Scholar, 2Zhao J. Shao J. Zhao R. et al.Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma.Thorac Cancer. 2018; 9: 129-135Crossref PubMed Scopus (7) Google Scholar A predisposition toward divergence of SCLC from LADC clones was shown at the early stages of LADC before any treatment4Lee J.K. Lee J. Kim S. et al.Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas.J Clin Oncol. 2017; 35: 3065-3074Crossref PubMed Scopus (268) Google Scholar; therefore, non-TKI treatment may also trigger SCLC transformation. Here, we present a case of LADC-to-SCLC transformation with primary resistance to gefitinib despite harboring of the EGFR exon 19 deletion. A 58-year-old female never-smoker presented with coughing and was referred to our hospital. Computed tomography revealed a 3-cm lump in the right lower pulmonary lobe (Fig. 1); percutaneous biopsy indicated LADC, whereas the results of brain magnetic resonance, bone scintigraphy, and abdomen ultrasonography were negative. The patient underwent a right lower lobectomy with systematic mediastinal and hilar lymph node (LN) dissection. Pathologic examination showed LADC without LN metastasis (T2aN0M0 according to the seventh edition of the American Joint Committee on Cancer staging system) (Fig. 2). The patient received no adjuvant therapy and was subjected to routine surveillance.Figure 2Rb, p53, and neuroendocrine markers in lung adenocarcinoma (LADC) and transformed SCLC. Immunohistochemistry results for Rb, p53, and neuroendocrine markers synaptophysin, chromogranin A, and CD56 are shown. Left column shows the primary LADC lesion (scale 100 μm). Middle column shows the SCLC cell block sections from supraclavicular lymph node biopsy, which were positive for synaptophysin, chromogranin A, and CD56 (scale 50 μm). Both the LADC and the SCLC cells were negative for Rb and p53. Right column shows wild-type (WT) controls for p53 and Rb (scale 100 μm).View Large Image Figure ViewerDownload Hi-res image Download (PPT) Forty-two months later, the patient exhibited dyspnea and cough. Computed tomography revealed a subcarinal lesion compressing the left main bronchus but no evidence of other metastases (see Fig. 1). She declined biopsy and immediately received pemetrexed plus carboplatin to constrain her rapidly progressing symptoms. In parallel, amplification refractory mutation system analysis revealed EGFR exon 19 deletion in the primary LADC. Her symptoms were greatly relieved after one cycle of chemotherapy, so she received two more cycles and subsequent radiotherapy to this lesion (60 Gy in 30 fractions), followed by pemetrexed consolidation (see Fig. 1). An enlarged mediastinal LN in her right tracheoesophageal groove was discovered at the completion of two cycles of pemetrexed treatment (see Fig. 1). She immediately received gefitinib but achieved no response. At 2 weeks after initiation of gefitinib therapy, the tumor had progressed to the left adrenal gland and left supraclavicular LN (see Fig. 1), and it further progressed to the liver by 2 months (see Fig. 1). We performed fine needle aspiration on the left supraclavicular LN. Immunohistochemistry was performed on cell block sections and revealed SCLC cells that were positive for synaptophysin, chromogranin A, and CD56 (see Fig. 2). The patient subsequently received two cycles of etoposide plus cisplatin. Her supraclavicular and right tracheoesophageal groove lesions recessed significantly (see Fig. 1); however, she presented evident fatigue, nausea, and multiple new lesions in the liver, and her adrenal lesions progressed. Her condition deteriorated rapidly and she was transferred to palliative care. To the best of our knowledge, this is the first report of SCLC transformation from EGFR-mutant LADC with primary resistance to TKIs. We consider it a case of bona fide SCLC transformation rather than a case with mixed histologic type or a second primary SCLC for several reasons. First, the resected primary LADC lesion was uniformly LADC without any SCLC components in the post hoc analysis (see Fig. 2). Second, there were 42 months between the initial diagnosis and recurrence, which was inconsistent with the aggressive behavior of SCLC (see Fig. 1). Lastly, the primary and transformed lesions shared the same EGFR driving mutation (exon 19 deletion E746-A750), which was double-confirmed by amplification refractory mutation system analysis and targeted sequencing. Inactivation of the tumor suppressors Rb and p53 has been shown to predict SCLC transformation in patients with EGFR TKI–treated LADC.4Lee J.K. Lee J. Kim S. et al.Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas.J Clin Oncol. 2017; 35: 3065-3074Crossref PubMed Scopus (268) Google Scholar In the present case, concurrent Rb and p53 inactivation was also found in both primary LADC and transformed SCLC cells (see Fig. 2), which is consistent with the findings in the aforementioned report. The presented evidence implies that SCLC transformation does not exclusively depend on EGFR TKI treatment and may be induced by chemotherapy and/or radiotherapy. Clinicians should be wary of SCLC transformation in LADCs that have relapsed after any treatments, and the importance of prompt rebiopsy should be emphasized in cases of suspected transformation. This study was supported by the National Natural Science Foundation of China (grant 81572963), Natural Science Foundation of Shanghai (grant 11ZR1407300), and Shanghai Pujiang Program (grant 15PJD008).